You have no items in your shopping cart.
Immunomodulators
In this section you will find Therapeutics Line of Treatment Immunomodulators market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.
| 9 Item(s) | Show per page |
| View as: List Grid |
Sort by
|
Analytical Tool - Cancer Therapeutic Antibodies
Published by BioSeeker Group on Mar 1st, 2010
€ 3,999.00
A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer antibody R&D and business development. Learn More
Analytical Tool- Cancer Immunotherapy
Published by BioSeeker Group on Mar 1st, 2010
€ 4,950.00
A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer immunotherapy. Learn More
Cancer Vaccines Drug Pipeline Update 2010
Published by BioSeeker Group on Jan 20th, 2010
€ 1,499.00
There are today 195 (165) companies plus partners developing 218 (194) cancer vaccine drugs in 360 (284) developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 175 (149) drugs. Cancer Vaccines Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 97 (84) different targets. Learn More
Antibodies in Oncology Drug Pipeline Update 2010
Published by BioSeeker Group on Jan 20th, 2010
€ 1,499.00
There are today 248 (223) companies plus partners developing 489 (463) antibody drugs in 956 (820) developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 287 (200) drugs. Antibodies In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 229 (195) different targets. Learn More
Immunotherapy in Oncology Drug Pipeline Update 2010
Published by BioSeeker Group on Jan 20th, 2010
€ 2,450.00
There are today 421 (291) companies plus partners developing 824 (396) cancer immunotherapy drugs in 1612 (674) developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 329 (178) drugs. Immunotherapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 315 (158) different targets. Learn More
Cytokine Therapy in Oncology Drug Pipeline Update 2010
Published by BioSeeker Group on Jan 20th, 2010
€ 999.00
There are today 69 companies plus partners developing 80 cytokine drugs in 143 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 8 drugs. Cytokine Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 19 different targets. Learn More
Immunotherapy in Oncology: Gaining Momentum
Published by BioSeeker Group on Aug 4th, 2006
€ 2,950.00
The immunotherapy field in cancer has never been more potent than it is right now, including block buster drugs like Avastin, Erbitux, and Rituxan. Antibodies are making the headlines but cancer vaccines are not far away. The recent approval of Gardasil, a cervical cancer vaccine, will certainly become a strong representative of its kind. Future challenges for the industry lie in discovering strong antigens, effective immunomodulators and developing suitable delivery technologies. Learn More
Competitive Outlook on Non-Antibody Based Cancer Vaccines
Published by BioSeeker Group on Aug 3rd, 2006
€ 1,950.00
Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline’s acquisition of Corixa will certainly push the industry towards more acquisitions. With this in mind, this report makes an in-depth assessment of competitive landscape, tumor antigen technologies, immunostimulatory strategies, vaccine delivery technologies, and a progress analysis of six major cancer vaccine indications. Learn More
The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave
Published by BioSeeker Group on Nov 22nd, 2005
€ 1,950.00
The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeutics. Learn More
| 9 Item(s) | Show per page |
| View as: List Grid |
Sort by
|